Jubilant Pharmova Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Jubilant Generics is a subsidiary of Jubilant Pharma, which is a wholly owned subsidiary of the company.

The said drug is primarily used to treat gastroesophageal reflux disease (GERD), heal acid-related damage to the esophagus.

The aforesaid tentative approval is subject to the expiry of the patent covering the currently listed Reference Listed Drug (RLD), which is expected to occur in December 2026. Final approval is anticipated upon such patent expiry.

The said approval follows successful completion of the pre-approval inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the solid dosage manufacturing facility located at Roorkee.

Jubilant Pharmova is an integrated global pharmaceutical company with three business segments, namely pharmaceuticals, contract research and development services, and proprietary novel drugs. The company?s consolidated net profit declined 22.27% to Rs 119.40 crore, while net sales rose 18.60% to Rs 2,272.20 crore in Q4 FY26 compared with Q4 FY25.

The scrip shed 0.84% to settle at Rs 964.05 on Thursday, 25th June 2026. The stock market is shut today on account of Muharram.

Powered by Capital Market - Live News

The inspection concluded with eight observations issued by the USFDA, none of which are related to sterility assurance concerns. The company said it will respond to the observations within 15 business days and remains committed to addressing them comprehensively.

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of Jubilant Pharmova.

Jubilant Pharmova is an integrated global pharmaceutical company with three business segments, namely pharmaceuticals, contract research and development services, and proprietary novel drugs. The company?s consolidated net profit declined 22.27% to Rs 119.40 crore, while net sales rose 18.60% to Rs 2,272.20 crore in Q4 FY26 compared with Q4 FY25.

Shares of Jubilant Pharmova shed 0.94% to Rs 965.45 on the BSE.

Powered by Capital Market - Live News

Jubilant Pharmova announced that United States Food and Drug Administration (USFDA) has concluded an inspection of Jubilant HollisterStier LLC (JHS)'s contract manufacturing facility located in Spokane, WA. U.S.A on 17 June 2026.

The USFDA had issued eight (8) observations, none of which are related to sterility assurance concerns.

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company.

Jubilant Pharmova announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.